Technology company Intellego has signed a five-year agreement with Zhongyou Medical (Likang), according to a press release.

The agreement covers exclusive sales and marketing rights in China for a product related to the disinfection market. Minimum volumes are said to be $360 million.

The deal is subject to, among other things, market approval from regulatory authorities. However, the parties do not foresee any significant regulatory hurdles, as the product has a low-risk classification and most of the documentation is already in place.

Intellego will need to continue to invest in the market together with Likang in the period leading up to market launch and beyond. Volumes will be achieved over a five-year period, with volumes gradually increasing over time. The sales launch is expected to take place by the end of 2025.

Intellego was halted by Nasdaq prior to the company's press release.